Dr Dana Rizk is Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham (UAB) and a VOYXACT VISIONARY Study Investigator and Co-Chair of the Steering Committee.

HOUSTON -- A novel self-administered shot that inhibits two key immunoregulatory cytokines reduced proteinuria in patients with IgA nephropathy, interim findings from the phase III ORIGIN 3 trial ...

Immunoglobulin A (IgA) nephropathy is an autoimmune condition that causes inflammation and damage in your kidneys, which may lead to kidney failure over time. IgA nephropathy develops when IgA builds ...

Chinook is a clinical-stage biopharmaceutical firm that is developing precision medicines for kidney diseases, including treatments for rare, chronic, and severe kidney conditions. Its lead program, ...

Treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (Farxiga) was safe and effective for slowing progression of chronic kidney disease (CKD) and the development of ...

Pietro A. Canetta, MD, MS, reflects on a particularly impactful case involving a young professional with IgA nephropathy, who was diagnosed after showing mild proteinuria and hematuria. Despite a ...

IgA nephropathy is hard to predict. But there’s one thing experts know. People with strong emotional and social support systems tend do better in the long run. And it’s best to live your life to the ...

Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that it was selected by Otsuka as the exclusive specialty pharmacy ...

The trial met its primary endpoint showing a statistically significant reduction in 24-hour uPCR with sibeprenlimab vs placebo in patients with IgA nephropathy. Topline interim results were announced ...

The FDA granted accelerated approval to iptacopan (Fabhalta) for primary immunoglobulin A (IgA) nephropathy, a rare progressive disease where the immune system attacks the kidneys, Novartis announced ...